Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Forget Sundial Growers, Buy This Calgary Company Instead

By Will Ashworth, InvestorPlace Contributor

Sundial Growers has a market capitalization of $1.73 billion. Based in Calgary, Alberta, SNDL stock isn't the best cannabis stock in the town.

Palantir CEO’s Billion-Dollar Payday Is Hardly Worth It

By Will Ashworth, InvestorPlace Contributor

Palantir filed its 2020 proxy on April 29. CEO Alex Karp made $1.1 billion in PLTR stock options. Will he be worth it? Peter Thiel hopes so.  

7 of the Biggest ETFs (That Deserve Even More)    

By Will Ashworth, InvestorPlace Contributor

In 2019, the 20 biggest ETFs accounted for 40% of the $4 trillion in assets under management. Seven of these funds continue to be smart buys.

Coinbase: Three Weeks After Its IPO, Is It a $400 or $200 Stock?

By Will Ashworth, InvestorPlace Contributor

Coinbase jumped 31% on its first day of trading. It’s been downhill since. Is Coinbase a $400 or $200 stock? Here’s a look at both arguments.

After a Steep Fall in 2021, Canopy Growth Is Now a Buy

By Will Ashworth, InvestorPlace Contributor

Piper Sandler analyst Michael Lavery called Canopy Growth expensive in February. But now trading at less than 15x 2022 sales, CGC stock is a buy.  

7 Hot Stocks to Consider for a Greener Future

By Will Ashworth, InvestorPlace Contributor

If you're looking for green hot stocks, the S&P Global Clean Energy Index is a good place to start. These seven names are some of the most promising picks of the bunch.

Ocugen Looks Perched and Ready to Blow Through $18

By Will Ashworth, InvestorPlace Contributor

Ocugen had a strong April gaining a whopping 87% for the month. OCGN stock is now up 313% on the year. It seems $18 is just around the corner.

Is Clover Health a Buy Ahead of Earnings?

By Will Ashworth, InvestorPlace Contributor

Clover Health reports first-quarter results on May 17. Given what we know about its 2020 results, is CLOV stock a buy ahead of earnings? 

Star Peak Energy Illustrates the Woes SPACs Face

By Will Ashworth, InvestorPlace Contributor

If you want to know how far SPACs have fallen in the eyes of investors, one needs to look at STPK stock and the merger vote with Stem Inc.    

The Opportunity for Social Capital Hedosophia Holdings V Remains the Same 

By Will Ashworth, InvestorPlace Contributor

Social Capital Hedosophia Holdings V refiled its S-4 to account for accounting changes on SPAC warrants. What does it mean for IPOE stock?

Load More